{
  "zip": "V7T 2X1",
  "sector": "Healthcare",
  "longBusinessSummary": "BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.",
  "city": "West Vancouver",
  "phone": "604 921 1810",
  "state": "BC",
  "country": "Canada",
  "companyOfficers": [],
  "website": "http://www.briacell.com",
  "maxAge": 1,
  "address1": "Bellevue Centre",
  "fax": "604 921 1898",
  "industry": "Biotechnology",
  "address2": "235 West 15th Street Suite 300",
  "previousClose": 5.43,
  "regularMarketOpen": 6.0536,
  "twoHundredDayAverage": 4.6574287,
  "trailingAnnualDividendYield": null,
  "payoutRatio": 0,
  "volume24Hr": null,
  "regularMarketDayHigh": 5.43,
  "navPrice": null,
  "averageDailyVolume10Day": 625,
  "totalAssets": null,
  "regularMarketPreviousClose": 5.43,
  "fiftyDayAverage": 4.322121,
  "trailingAnnualDividendRate": null,
  "open": 6.0536,
  "averageVolume10days": 625,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": 2.023762,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 5.43,
  "priceHint": 2,
  "currency": "USD",
  "regularMarketVolume": 1668,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 4251657,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 680,
  "priceToSalesTrailing12Months": null,
  "dayLow": 5.43,
  "ask": 0,
  "ytdReturn": null,
  "askSize": 0,
  "volume": 1668,
  "fiftyTwoWeekHigh": 20.36,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 3.25,
  "bid": 0,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": 0,
  "dayHigh": 5.43,
  "exchange": "PNK",
  "shortName": "BRIACELL THERAPEUTICS CORP",
  "longName": "BriaCell Therapeutics Corp.",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "BCTXF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_262266102",
  "uuid": "df114aa9-8e79-3284-a852-cbaee0bdcdba",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": 0,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 771962,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": 0.002,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1596153600,
  "heldPercentInstitutions": 0.001,
  "netIncomeToCommon": null,
  "trailingEps": -0.031,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": 2714.9998,
  "heldPercentInsiders": 0.15835,
  "nextFiscalYearEnd": 1659225600,
  "mostRecentQuarter": 1604102400,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 480284,
  "enterpriseValue": 4191753,
  "threeYearAverageReturn": null,
  "lastSplitDate": 1577923200,
  "lastSplitFactor": "1:300",
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 6.0536,
  "logo_url": "https://logo.clearbit.com/briacell.com"
}